Drug Type Small molecule drug |
Synonyms Citalopram/pipamperone, Pipamperone/citalopram, PipCit + [1] |
Action antagonists, inhibitors |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), D4 receptor antagonists(Dopamine D4 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H31ClFN3O2 |
InChIKeyUBQRWZFMJULMLP-UHFFFAOYSA-N |
CAS Registry2448-68-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 3 | United States | 01 Sep 2011 | |
Depressive Disorder, Major | Phase 3 | Canada | 01 Sep 2011 |
Phase 3 | 555 | ypyarzyppq = vmalzedgty ublnrhzdsh (glmbpomxkn, csvriwzdji - lkewfvtocs) View more | - | 07 Apr 2022 | |||
(Citalopram) | ypyarzyppq = gbkvxbkays ublnrhzdsh (glmbpomxkn, tjzodtjddw - pvuvpfxcem) View more |